Engineered Bacteria by NUS Offers Breakthrough Brain Support via Liver Pathway

Researchers at the National University of Singapore (NUS) have engineered strains of beneficial gut bacteria to act as “living medicines” that reduce toxic buildup linked to severe liver-related brain dysfunction. The breakthrough, published on April 24, 2026, in the peer-reviewed journal Cell, offers a programmable approach to restoring metabolic balance across the gut, liver and brain in patients with liver failure.

Engineered Bacteria Target Toxins at the Source

The NUS team, led by Professor Matthew Chang and including Associate Professor Jonathan Lee and Dr. Nikhil Aggarwal, modified two naturally occurring bacterial strains to absorb ammonia and break down L-glutamine—key toxins that accumulate when the liver fails. In preclinical models, the engineered bacteria reduced toxin levels by up to 10 times, bringing ammonia concentrations in the brain to levels comparable to those in healthy conditions.

Liver failure disrupts the body’s ability to filter ammonia from the blood, allowing the toxin to reach the brain and trigger hepatic encephalopathy (HE). This neurological complication can cause anxiety, confusion, memory loss, and, in severe cases, coma or death. HE is a common and devastating consequence of liver cirrhosis, affecting a significant portion of patients with advanced liver disease.

A Modular Platform for Metabolic Disorders

The study positions engineered commensal bacteria as a responsive platform for multi-metabolite modulation. Unlike conventional treatments, which often focus on symptom management, this approach targets the root cause by reprogramming the gut microbiome to intercept toxins before they enter systemic circulation. The bacteria function as self-sustaining therapeutic agents, capable of adapting to the host’s metabolic environment.

The researchers emphasized the potential of this strategy beyond liver disease. “These findings establish engineered commensals as a modular, responsive platform for multi-metabolite modulation of host-microbiota metabolism,” the study states. The approach could be adapted to address other disorders of the gut-liver-brain axis, including metabolic diseases with systemic effects.

Safety and Efficacy Over Current Treatments

Current treatments for hepatic encephalopathy, such as lactulose and rifaximin, aim to reduce ammonia production or absorption but often come with side effects and limited efficacy. The NUS team’s engineered bacteria offer a more targeted solution, directly neutralizing toxins in the gut before they can reach the brain. The study’s results suggest this method is both safer and more effective, with the potential to improve long-term outcomes for patients with liver failure.

The researchers also highlighted the precision of engineered bacteria as delivery vehicles for brain-targeted therapies. “This study illustrates the potential of engineered bacteria to serve as precise delivery vehicles for brain-targeted therapies,” said Dr. Shen, a collaborator on the project, in earlier remarks published in February 2025. The programmable nature of the bacteria allows for tailored interventions based on individual patient needs.

Path to Clinical Application

The NUS team is now focused on advancing the technology toward clinical use. While the study’s findings are based on preclinical models, the researchers are optimistic about the potential for human trials. If successful, the engineered bacteria could provide a new standard of care for patients with liver failure and other metabolic disorders, offering a more sustainable and less invasive alternative to existing treatments.

The publication of the study in Cell underscores the significance of the research, as the journal is known for featuring high-impact discoveries in the life sciences. The eight-year project reflects the growing intersection of synthetic biology and clinical medicine, where engineered microbes are increasingly explored as therapeutic tools.

Broader Implications for Gut-Brain Health

The gut-brain axis has emerged as a critical area of research in recent years, with studies linking gut microbiome composition to neurological and psychiatric conditions. The NUS team’s work adds to this body of evidence, demonstrating how engineered bacteria can be harnessed to correct metabolic imbalances that contribute to brain dysfunction.

While the immediate focus is on liver-related brain disorders, the platform’s modularity suggests broader applications. Future research may explore its potential in treating conditions such as Parkinson’s disease, Alzheimer’s disease, and other neurodegenerative disorders where gut-brain interactions play a role.

For now, the NUS team’s breakthrough offers hope for patients with hepatic encephalopathy, a condition with limited treatment options and high mortality rates. By reprogramming the gut microbiome, the researchers have opened a new frontier in the fight against liver-related brain dysfunction, one that could redefine therapeutic approaches to metabolic diseases.